Solid Biosciences Inc. Income Tax Examination, Penalties and Interest Expense
Solid Biosciences Inc. (SLDB) reported Income Tax Examination, Penalties and Interest Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Interest Expense
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2026-03-19
- Solid Biosciences Inc. income tax examination, penalties and interest expense for the quarter ending 2018-12-31 was $0.00.
- Solid Biosciences Inc. income tax examination, penalties and interest expense for the quarter ending 2018-09-30 was $0.00.
- Solid Biosciences Inc. income tax examination, penalties and interest expense for the quarter ending 2018-06-30 was $0.00.
- Solid Biosciences Inc. income tax examination, penalties and interest expense for the quarter ending 2018-03-31 was $0.00.
- Solid Biosciences Inc. income tax examination, penalties and interest expense for fiscal 2025 was $0.00.
- Solid Biosciences Inc. income tax examination, penalties and interest expense for fiscal 2024 was $0.00.
- Solid Biosciences Inc. income tax examination, penalties and interest expense for fiscal 2023 was $0.00.
- Solid Biosciences Inc. income tax examination, penalties and interest expense for fiscal 2022 was $0.00.
| Period end | Income Tax Examination, Penalties and Interest Expense 3 month | Income Tax Examination, Penalties and Interest Expense 6 month | Income Tax Examination, Penalties and Interest Expense 9 month | Income Tax Examination, Penalties and Interest Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-19 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-19 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-06 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-13 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-23 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-14 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-15 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | $0.00 10-K · filed 2020-03-12 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $0.00 derived: sum of 2 quarters · filed 2018-11-13 | $0.00 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $0.00 10-Q · filed 2018-08-10 | ||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |